tbResList Print — MushPL Mushroom Phellinus. linteus

Filters: qv=131, qv2=%, rfv=%

Product

MushPL Mushroom Phellinus. linteus
Description: <p><b>Mushroom Phellinus linteus</b> — a medicinal basidiomycete mushroom historically used in East Asian medicine and commonly called sanghuang, Meshima, Meshimakobu, or song gen. It is best regarded as a complex natural-product food source rather than a single pharmacologic compound; preparations include fruiting-body extracts, cultured mycelial extracts, protein-bound polysaccharides, β-glucan-rich fractions, and phenolic constituents such as hispolon. The abbreviation PL is widely used for Phellinus linteus extracts, with PLP commonly used for Phellinus linteus polysaccharides. Modern molecular taxonomy shows that many medicinal strains historically labeled <i>Phellinus linteus</i> are actually members of the genus <i>Sanghuangporus</i>, particularly <i>Sanghuangporus sanghuang</i>; therefore, biological activity cannot automatically be assumed equivalent across products carrying the historical PL name. Anticancer evidence is predominantly preclinical, although human immune-function RCTs and limited observational/case-level cancer evidence exist.</p>

<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Immune-mediated antitumor activity — polysaccharide-rich extracts activate macrophage and natural-killer-cell responses and can increase tumoricidal immune activity; human studies demonstrate increased NK-cell activity after oral PL extract.</li>
<li>Apoptosis induction — several PL fractions and the phenolic constituent hispolon activate intrinsic and extrinsic apoptotic signaling, including caspase-3, caspase-8, caspase-9, cytochrome-c release, death-receptor signaling, and altered Bax/Bcl-2 balance.</li>
<li>Suppression of proliferative and survival signaling — reported effects include ↓ PI3K/AKT signaling, ↓ cyclin/CDK activity, ↑ p21/p27, and cell-cycle arrest.</li>
<li>Wnt/β-catenin inhibition — protein-bound PL polysaccharides can ↓ β-catenin, cyclin D1 and TCF/LEF transcription, reducing proliferation and tumor growth in colorectal cancer models.</li>
<li>Suppression of invasion and metastasis — PL preparations can ↓ MMP-2/MMP-9 activity, motility and invasive behavior in several experimental tumor models.</li>
<li>Anti-angiogenic activity — PL polysaccharide preparations have inhibited endothelial-cell proliferation, tube formation and tumor microvessel density in preclinical models.</li>
<li>ROS modulation and oxidative-stress signaling — some extracts and hispolon increase oxidative stress sufficiently to promote apoptosis, whereas other PL polysaccharide preparations reduce intracellular ROS; this mechanism is strongly preparation- and model-dependent rather than a uniform property of PL.</li>
<li>Chemosensitization — preclinical evidence indicates enhancement of responses to agents such as doxorubicin and sensitization to TRAIL-mediated apoptosis, but this has not been established as a clinical cancer-treatment effect.</li>
</ol>

<p><b>Bioavailability / PK relevance:</b> PL is not a chemically uniform drug, so a single pharmacokinetic profile does not exist. High-molecular-weight fungal polysaccharides and β-glucans have limited conventional systemic absorption and may act substantially through intestinal and immune signaling, whereas lower-molecular-weight phenolics such as hispolon represent chemically distinct constituents. Extract composition, fungal species, fruiting body versus mycelium, culture conditions, and extraction method substantially affect biological activity. Human oral studies have used standardized PL extracts at approximately 1–2 g/day for eight weeks, but these doses cannot be directly translated to purified polysaccharide or hispolon exposure.</p>

<p><b>In-vitro vs systemic exposure relevance:</b> Many direct cancer-cell experiments use PL extracts at approximately 100–1000 µg/mL or purified compounds at micromolar concentrations. Comparable concentrations of intact crude extract in human plasma have not been demonstrated and should not be assumed achievable after oral consumption. Direct cytotoxic mechanisms therefore have lower translational confidence than immune-mediated effects demonstrated following oral administration.</p>

<p><b>Clinical evidence status:</b> Preclinical anticancer evidence is extensive; cancer-specific clinical evidence remains limited. A randomized double-blind placebo-controlled study in 98 adults receiving 1000 mg/day for eight weeks reported increased NK-cell activity and no PL-related liver or renal toxicity, but it was an immune-function study rather than a cancer-treatment trial. A separate small randomized pilot evaluated 1000–2000 mg/day with no major safety signal. Cancer evidence includes isolated case reports and a recent retrospective cohort of patients with resected pancreatic cancer receiving PL alongside adjuvant chemotherapy; the latter reported longer overall survival but cannot establish causality because treatment was non-randomized. PL should therefore be categorized as a preclinical/early-human adjunct candidate rather than an established anticancer therapy.</p>

<p><b>Regulatory / safety relevance:</b> PL-containing natural-health products are marketed in jurisdictions including Canada, and standardized products have been used clinically in Korea, but this does not constitute approval as an anticancer treatment. Human short-term studies suggest oral extracts are generally well tolerated. Immune stimulation is potentially relevant in autoimmune disease or with immunosuppressive therapy; Canadian licensed-product information includes cautions concerning immunosuppressants and autoimmune or immune-system disorders. Product identity and standardization are important because the historical term <i>Phellinus linteus</i> encompasses taxonomically distinct medicinal strains.</p>


<h3>Mechanistic Effects of Phellinus linteus</h3>
<table>
<thead>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Antitumor Immune Activation</td>
<td>↓ tumor survival indirectly</td>
<td>↑ NK-cell and macrophage tumoricidal activity</td>
<td>Immune-mediated tumor suppression</td>
<td>Particularly associated with polysaccharide-rich fractions; one of the more translationally credible mechanisms because oral human studies demonstrate ↑ NK-cell activity.</td>
</tr>
<tr>
<td>2</td>
<td>Intrinsic and Extrinsic Apoptosis</td>
<td>↑ caspase-3, caspase-8, caspase-9; ↑ Bax/Bcl-2 ratio; ↑ cytochrome c; ↑ death-receptor signaling</td>
<td>Variable; comparatively limited direct cytotoxicity reported for some preparations</td>
<td>Programmed cancer-cell death</td>
<td>Observed with protein-bound polysaccharides, crude extracts and hispolon; mechanism varies substantially with preparation and cancer model.</td>
</tr>
<tr>
<td>3</td>
<td>PI3K AKT Survival Signaling</td>
<td>↓ AKT signaling; ↑ PTEN-related signaling (model-dependent)</td>
<td>Insufficiently characterized</td>
<td>↓ survival and proliferation</td>
<td>Reported particularly in hepatocellular and prostate cancer models; not established clinically.</td>
</tr>
<tr>
<td>4</td>
<td>Cell Cycle Control</td>
<td>↓ cyclin D1; ↓ cyclin E; ↓ CDK2/CDK4; ↑ p21/p27</td>
<td>Insufficiently characterized</td>
<td>G0/G1 or G2/M arrest (model-dependent)</td>
<td>The arrest point depends on the PL constituent, extract and cell line.</td>
</tr>
<tr>
<td>5</td>
<td>Wnt β-catenin Signaling</td>
<td>↓ β-catenin; ↓ TCF/LEF activity; ↓ cyclin D1</td>
<td>Insufficiently characterized</td>
<td>↓ proliferation and tumor growth</td>
<td>Strongly demonstrated with protein-bound polysaccharide in SW480 colorectal cancer models.</td>
</tr>
<tr>
<td>6</td>
<td>Invasion and Metastasis</td>
<td>↓ MMP-2/MMP-9; ↓ migration; ↓ invasion</td>
<td>Limited evidence</td>
<td>Reduced metastatic phenotype</td>
<td>Supported by multiple preclinical preparations; effects should not be generalized to all PL products.</td>
</tr>
<tr>
<td>7</td>
<td>Tumor Angiogenesis</td>
<td>↓ tumor microvessel density</td>
<td>↓ endothelial proliferation and tube formation</td>
<td>Reduced angiogenesis</td>
<td>Demonstrated preclinically with protein-bound polysaccharides; systemic effects on normal angiogenesis have not been adequately characterized.</td>
</tr>
<tr>
<td>8</td>
<td>Mitochondrial Stress</td>
<td>↓ mitochondrial membrane potential; ↑ cytochrome-c release (model-dependent)</td>
<td>Variable</td>
<td>Intrinsic apoptosis</td>
<td>Particularly described for hispolon and selected PL fractions.</td>
</tr>
<tr>
<td>9</td>
<td>ROS and Oxidative Stress</td>
<td>↑ or ↓ ROS (context-dependent); ↑ oxidative apoptosis with selected extracts</td>
<td>Antioxidant or immune-modulatory effects reported</td>
<td>Context-dependent redox modulation</td>
<td>Not a single-direction mechanism. Some anticancer preparations induce ROS, whereas recent PL polysaccharide studies report ↓ ROS.</td>
</tr>
<tr>
<td>10</td>
<td>TRAIL Sensitization</td>
<td>↑ death receptors; ↓ cFLIP/Bcl-2/Bcl-xL; ↑ TRAIL-induced apoptosis</td>
<td>Insufficiently characterized</td>
<td>Chemosensitization</td>
<td>Primarily demonstrated with hispolon; requires external apoptotic stimulus and remains preclinical.</td>
</tr>
<tr>
<td>11</td>
<td>Clinical Translation Constraint</td>
<td>Direct in-vitro effects often require relatively high extract concentrations</td>
<td>Short-term oral human studies suggest reasonable tolerability</td>
<td>Limits extrapolation from laboratory studies</td>
<td>Major constraints are uncertain systemic exposure, non-standardized extracts, taxonomic heterogeneity, absence of randomized cancer-treatment trials, and possible immune-related interactions.</td>
</tr>
</tbody>
</table>

Pathway results for Effect on Cancer / Diseased Cells

Total Targets: 0

Pathway results for Effect on Normal Cells

Total Targets: 0

Research papers

Year Title Authors PMID Link Flag